Truist Financial analyst Joon Lee maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) on November 15 and set a price target of $6.00. The company’s shares closed yesterday at $0.89.
According to TipRanks, Lee is a 4-star analyst with an average return of 9.8% and a 39.68% success rate. Lee covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Ultragenyx Pharmaceutical, and Axsome Therapeutics.
In addition to Truist Financial, Adverum Biotechnologies also received a Buy from TD Cowen’s Joseph Thome in a report issued on November 9. However, on the same day, RBC Capital maintained a Hold rating on Adverum Biotechnologies (NASDAQ: ADVM).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.34 and a one-year low of $0.53. Currently, Adverum Biotechnologies has an average volume of 236.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adverum Biotechnologies (ADVM) Company Description:
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
Read More on ADVM:
- Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- ADVM Upcoming Earnings Report: What to Expect?
- Adverum appoints C. David Nicholson to board of directors
- Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
- Adverum announces 3-year efficacy, safety results from OPTIC extension study
